The latest medical insurance reimbursement policy for lenalidomide

Lenalidomide (Lenalidomide) is an immunomodulatory drug that belongs to a class of drugs developed by Veatch Pharmaceuticals. Its main ingredient is lenalidomide, which usually comes in capsule form. Lenalidomide is widely used to treat a variety of hematological malignancies, especially multiple myeloma (MM) and myelodysplastic syndromes (Myelodysplastic Syndromes, MDS). In addition, it is also used to treat lymphoproliferative disorders (Lymphoproliferative Disorders).

Medical insurance reimbursement is limited only to: 1. In combination with dexamethasone, for the treatment of adult patients with previously untreated multiple myeloma who are not suitable for transplantation;2. In combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy;3. In combination with rituximab, for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

Lenalidomide has been approved for marketing in China and has been included in the national medical insurance system. Therefore, patients can purchase this drug domestically without traveling overseas. The price is about four to five thousand yuan, but the specific price and medical insurance reimbursement policy may vary slightly depending on the region. It is recommended that patients go to the pharmacy of the local hospital for detailed consultation.

It is worth mentioning that there are some more affordable generic lenalidomide drugs on the foreign market, such as the versions produced in Laos, Bangladesh, India and other places, which sell for only a few hundred yuan. After comparison, the pharmaceutical ingredients of these foreign generic drugs and domestic original drugs are basically consistent.

Lenalidomide can inhibit the proliferation of various types of tumor cells and reduce the number of tumor cells. It can also promote apoptosis of tumor cells, which means causing abnormal cells to die on their own, thereby reducing the burden of tumors. Lenalidomide can regulate the function of the immune system and enhance the body's immune response to tumors, thereby helping the body eliminate tumor cells more effectively.

However, although lenalidomide has shown significant efficacy in the treatment of malignant tumors, it may also cause a series of adverse reactions, such as anemia, leukopenia, gastrointestinal discomfort, skin reactions, etc. Therefore, doctors usually closely monitor the patient's condition and drug tolerance while using lenalidomide, and adjust the dose or take other treatment measures as needed.